www.fdanews.com/articles/130990-lundbeck-and-merck-sign-commercialization-agreement-for-sycrest

Lundbeck and Merck Sign Commercialization Agreement for Sycrest

October 12, 2010

H. Lundbeck A/S and Merck Tuesday announced a commercialization agreement for Sycrest (asenapine) sublingual tablets (5 mg, 10 mg).
StreetInsider